<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00092443</url>
  </required_header>
  <id_info>
    <org_study_id>V260-007</org_study_id>
    <secondary_id>2004_077</secondary_id>
    <nct_id>NCT00092443</nct_id>
  </id_info>
  <brief_title>Dose Confirmation Efficacy Study (V260-007)</brief_title>
  <official_title>Study of the Efficacy, Safety, and Immunogenicity of V260 at Expiry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the safety of the investigational Rotavirus Vaccine and
      the efficacy to prevent Rotavirus Gastroenteritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of treatment is 10 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of Clinical Rotavirus Disease Caused by the Composite of the Serotypes Contained Within the Vaccine More Than 14 Days Following the Third Dose.</measure>
    <time_frame>At least 14 days following the 3rd vaccination</time_frame>
    <description>G1, G2, G3, and G4 Serotype Rotavirus Gastroenteritis Cases Occurring at Least 14 Days Postdose 3 Through the First Rotavirus Season Postvaccination in the Per-Protocol Population Using Per-Protocol Case Definition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With ≥3 Fold Rise in Antibody Titer</measure>
    <time_frame>14 days following the 3rd vaccination</time_frame>
    <description>Induction of postdose 3 rotavirus Serum neutralizing antibody (SNA) response (Number of subjects with ≥3 fold rise in antibody titer)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1312</enrollment>
  <condition>Rotavirus Infections</condition>
  <arm_group>
    <arm_group_label>RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent)
administered 28 to 70 days apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo matching RotaTeq™</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching RotaTeq™ administered 28 to 70 days apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RotaTeq™, rotavirus vaccine, live, oral, pentavalent</intervention_name>
    <description>Three doses of RotaTeq™ administered 28 to 70 days apart.</description>
    <arm_group_label>RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose)</arm_group_label>
    <other_name>V260</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Placebo matching RotaTeq™</intervention_name>
    <description>Placebo matching RotaTeq™ administered 28 to 70 days apart.</description>
    <arm_group_label>Placebo matching RotaTeq™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy infants

        Exclusion Criteria:

          -  History of abdominal disorders from a birth defect, intussusception, or abdominal
             surgery

          -  Known or suspected problems with immune system

          -  Fever at time of immunization

          -  Prior administration of a rotavirus vaccine

          -  History of known prior rotavirus disease

          -  Chronic diarrhea, or failure to thrive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Block SL, Vesikari T, Goveia MG, Rivers SB, Adeyi BA, Dallas MJ, Bauder J, Boslego JW, Heaton PM; Pentavalent Rotavirus Vaccine Dose Confirmation Efficacy Study Group. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics. 2007 Jan;119(1):11-8.</citation>
    <PMID>17200266</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2004</study_first_submitted>
  <study_first_submitted_qc>September 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2004</study_first_posted>
  <results_first_submitted>May 19, 2009</results_first_submitted>
  <results_first_submitted_qc>May 19, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 10, 2009</results_first_posted>
  <last_update_submitted>September 11, 2015</last_update_submitted>
  <last_update_submitted_qc>September 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 30 sites - 27 in the United States, and 3 in Finland from 24-Sep-2002 (first
patient in) to 11-Feb-2004 (last dose given).
Last subject completed follow-up: 08-Jun-2004.
All data corrections applied (Frozen File): 07-Sep-2004</recruitment_details>
      <pre_assignment_details>Excluded from the trial before assignment to groups were patients with: history of congenital abdominal
disorders, intussusception, or abdominal surgery; history of known prior rotavirus disease, chronic diarrhea,
or failure to thrive.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose)</title>
          <description>Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent) administered 28 to 70 days apart, with up to 42 days of safety follow-up after each vaccination, and followup for acute gastrointestinal episodes (AGEs) through the first rotavirus season post vaccination.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Matching RotaTeq™</title>
          <description>Placebo matching RotaTeq™ administered 28 to 70 days apart, with up to 42 days of safety follow-up after each vaccination and follow-up for acute gastrointestinal episodes (AGEs) through the first rotavirus season post vaccination.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="651">Subjects who passed all entry criteria and who were randomized in to the study</participants>
                <participants group_id="P2" count="661">Subjects who passed all entry criteria and who were randomized in to the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated at Visit 1</title>
              <participants_list>
                <participants group_id="P1" count="650"/>
                <participants group_id="P2" count="660"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated at Visit 2</title>
              <participants_list>
                <participants group_id="P1" count="618"/>
                <participants group_id="P2" count="627"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated at Visit 3</title>
              <participants_list>
                <participants group_id="P1" count="593"/>
                <participants group_id="P2" count="608"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="593">Subjects vaccinated and followed up 42 days after each dose, thru 1st rotavirus season post study</participants>
                <participants group_id="P2" count="607">Subjects vaccinated and followed up 42 days after each dose, thru 1st rotavirus season post study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose)</title>
          <description>Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent) administered 28 to 70 days apart, with up to 42 days of safety follow-up after each vaccination, and followup for acute gastrointestinal episodes (AGEs) through the first rotavirus season post vaccination.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Matching RotaTeq™</title>
          <description>Placebo matching RotaTeq™ administered 28 to 70 days apart, with up to 42 days of safety follow-up after each vaccination and follow-up for acute gastrointestinal episodes (AGEs) through the first rotavirus season post vaccination.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="651"/>
            <count group_id="B2" value="661"/>
            <count group_id="B3" value="1312"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>6 to 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="648"/>
                    <measurement group_id="B2" value="658"/>
                    <measurement group_id="B3" value="1306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Over 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="323"/>
                    <measurement group_id="B3" value="627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="347"/>
                    <measurement group_id="B2" value="338"/>
                    <measurement group_id="B3" value="685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="525"/>
                    <measurement group_id="B2" value="540"/>
                    <measurement group_id="B3" value="1065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi-Racial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Occurence of Clinical Rotavirus Disease Caused by the Composite of the Serotypes Contained Within the Vaccine More Than 14 Days Following the Third Dose.</title>
        <description>G1, G2, G3, and G4 Serotype Rotavirus Gastroenteritis Cases Occurring at Least 14 Days Postdose 3 Through the First Rotavirus Season Postvaccination in the Per-Protocol Population Using Per-Protocol Case Definition</description>
        <time_frame>At least 14 days following the 3rd vaccination</time_frame>
        <population>Per Protocol Population; number randomized is different from number analyzed due to some data excluded from the analysis (e.g., unevaluable due to wild-type rotavirus-positive stool antigen Enzyme immunoassay (EIA) prior to 14 days Postdose 3, incomplete clinical and/or laboratory results, or stool samples collected out of day range.</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ at Expiry Potency (≈1.1 x 107 IU/Dose)</title>
            <description>Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent) administered 28 to 70 days apart, with up to 42 days of safety follow-up after each vaccination, and follow-up for acute gastrointestinal episodes (AGEs) through the first rotavirus season post vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Matching RotaTeq™</title>
            <description>Placebo matching RotaTeq™ administered 28 to 70 days apart, with up to 42 days of safety follow-up after each vaccination and follow-up for AGEs through the first rotavirus season post vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurence of Clinical Rotavirus Disease Caused by the Composite of the Serotypes Contained Within the Vaccine More Than 14 Days Following the Third Dose.</title>
          <description>G1, G2, G3, and G4 Serotype Rotavirus Gastroenteritis Cases Occurring at Least 14 Days Postdose 3 Through the First Rotavirus Season Postvaccination in the Per-Protocol Population Using Per-Protocol Case Definition</description>
          <population>Per Protocol Population; number randomized is different from number analyzed due to some data excluded from the analysis (e.g., unevaluable due to wild-type rotavirus-positive stool antigen Enzyme immunoassay (EIA) prior to 14 days Postdose 3, incomplete clinical and/or laboratory results, or stool samples collected out of day range.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="551"/>
                <count group_id="O2" value="564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Exact Binomial Test</method>
            <param_type>Efficacy = 1-Relative Risk</param_type>
            <param_value>72.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>50.6</ci_lower_limit>
            <ci_upper_limit>85.6</ci_upper_limit>
            <estimate_desc>Efficacy = 1-RR, expressed as a percentage; the RR is the incidence in the vaccine group / the incidence in the placebo group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With ≥3 Fold Rise in Antibody Titer</title>
        <description>Induction of postdose 3 rotavirus Serum neutralizing antibody (SNA) response (Number of subjects with ≥3 fold rise in antibody titer)</description>
        <time_frame>14 days following the 3rd vaccination</time_frame>
        <population>Per Protocol Population; number randomized is different from number analyzed due to some data excluded from the analysis (e.g., unevaluable due to wild-type rotavirus-positive stool antigen EIA prior to 14 days Postdose 3, incomplete clinical and/or laboratory results, or stool samples collected out of day range.</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ at Expiry Potency (SNA - G1)</title>
            <description>Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations.</description>
          </group>
          <group group_id="O2">
            <title>RotaTeq™ at Expiry Potency (SNA - G2)</title>
            <description>Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations.</description>
          </group>
          <group group_id="O3">
            <title>RotaTeq™ at Expiry Potency (SNA - G3)</title>
            <description>Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations.</description>
          </group>
          <group group_id="O4">
            <title>RotaTeq™ at Expiry Potency (SNA - G4)</title>
            <description>Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations.</description>
          </group>
          <group group_id="O5">
            <title>RotaTeq™ at Expiry Potency (SNA - P1A)</title>
            <description>Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Matching RotaTeq™ (SNA - G1)</title>
            <description>Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Matching RotaTeq™ (SNA - G2)</title>
            <description>Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Matching RotaTeq™ (SNA - G3)</title>
            <description>Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Matching RotaTeq™ (SNA - G4)</title>
            <description>Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations.</description>
          </group>
          <group group_id="O10">
            <title>Placebo Matching RotaTeq™ (SNA - P1A)</title>
            <description>Subjects tested with data available for analysis excluding protocol violators and subjects with invalid data based on lab determinations.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With ≥3 Fold Rise in Antibody Titer</title>
          <description>Induction of postdose 3 rotavirus Serum neutralizing antibody (SNA) response (Number of subjects with ≥3 fold rise in antibody titer)</description>
          <population>Per Protocol Population; number randomized is different from number analyzed due to some data excluded from the analysis (e.g., unevaluable due to wild-type rotavirus-positive stool antigen EIA prior to 14 days Postdose 3, incomplete clinical and/or laboratory results, or stool samples collected out of day range.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="70"/>
                <count group_id="O8" value="75"/>
                <count group_id="O9" value="70"/>
                <count group_id="O10" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent of Participants</param_type>
            <param_value>56.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>44.0</ci_lower_limit>
            <ci_upper_limit>66.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent of Participants</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent of Participants</param_type>
            <param_value>14.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.9</ci_lower_limit>
            <ci_upper_limit>25.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent of Participants</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent of Participants</param_type>
            <param_value>9.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.4</ci_lower_limit>
            <ci_upper_limit>18.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent of Participants</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>4.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent of Participants</param_type>
            <param_value>39.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>27.6</ci_lower_limit>
            <ci_upper_limit>52.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent of Participants</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>7.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent of Participants</param_type>
            <param_value>24.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>14.5</ci_lower_limit>
            <ci_upper_limit>37.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent of Participants</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose)</title>
          <description>Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent) administered 28 to 70 days apart, with up to 42 days of safety follow-up after each vaccination, and follow-up for acute gastrointestinal episodes (AGEs) through the first rotavirus season post vaccination.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Matching RotaTeq™</title>
          <description>Placebo matching RotaTeq™ administered 28 to 70 days apart, with up to 42 days of safety follow-up after each vaccination and follow-up for AGEs through the first rotavirus season post vaccination.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="649"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="649"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="649"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="649"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="649"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="649"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="649"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="649"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="649"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="649"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="649"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="649"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="649"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="649"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="649"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="649"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="649"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="649"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="649"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="649"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="649"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="649"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="649"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="649"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="649"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="649"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Spinal cord neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="649"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="649"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="649"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="649"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="649"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="649"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="558" subjects_at_risk="649"/>
                <counts group_id="E2" subjects_affected="565" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="56" subjects_affected="50" subjects_at_risk="649"/>
                <counts group_id="E2" events="53" subjects_affected="46" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="39" subjects_affected="35" subjects_at_risk="649"/>
                <counts group_id="E2" events="38" subjects_affected="34" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="160" subjects_affected="103" subjects_at_risk="649"/>
                <counts group_id="E2" events="177" subjects_affected="110" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="72" subjects_affected="52" subjects_at_risk="649"/>
                <counts group_id="E2" events="78" subjects_affected="49" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Regurgitation of food</sub_title>
                <counts group_id="E1" events="54" subjects_affected="44" subjects_at_risk="649"/>
                <counts group_id="E2" events="55" subjects_affected="41" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="112" subjects_affected="81" subjects_at_risk="649"/>
                <counts group_id="E2" events="116" subjects_affected="77" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="82" subjects_affected="61" subjects_at_risk="649"/>
                <counts group_id="E2" events="81" subjects_affected="62" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="450" subjects_affected="283" subjects_at_risk="649"/>
                <counts group_id="E2" events="438" subjects_affected="265" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="103" subjects_affected="91" subjects_at_risk="649"/>
                <counts group_id="E2" events="132" subjects_affected="106" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="143" subjects_affected="119" subjects_at_risk="649"/>
                <counts group_id="E2" events="144" subjects_affected="111" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="46" subjects_affected="41" subjects_at_risk="649"/>
                <counts group_id="E2" events="32" subjects_affected="28" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="84" subjects_affected="69" subjects_at_risk="649"/>
                <counts group_id="E2" events="110" subjects_affected="81" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="192" subjects_affected="150" subjects_at_risk="649"/>
                <counts group_id="E2" events="172" subjects_affected="143" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="145" subjects_affected="102" subjects_at_risk="649"/>
                <counts group_id="E2" events="145" subjects_affected="99" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="82" subjects_affected="53" subjects_at_risk="649"/>
                <counts group_id="E2" events="79" subjects_affected="52" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="248" subjects_affected="155" subjects_at_risk="649"/>
                <counts group_id="E2" events="299" subjects_affected="172" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="111" subjects_affected="95" subjects_at_risk="649"/>
                <counts group_id="E2" events="106" subjects_affected="90" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="47" subjects_affected="39" subjects_at_risk="649"/>
                <counts group_id="E2" events="68" subjects_affected="53" subjects_at_risk="658"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="73" subjects_affected="59" subjects_at_risk="649"/>
                <counts group_id="E2" events="50" subjects_affected="42" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Safety has been reported in the literature.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Vice President, Late Stage Development Group Leader</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

